Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

Barbara Burtness, MD
Published: Wednesday, Jul 19, 2017



Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

In an investigator-initiated trial at Yale Cancer Center, patients with persistent disease after radiation are being exposed to pembrolizumab (Keytruda) in hope of initiating an immune response prior to salvage therapy.
 
SELECTED
LANGUAGE


Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

In an investigator-initiated trial at Yale Cancer Center, patients with persistent disease after radiation are being exposed to pembrolizumab (Keytruda) in hope of initiating an immune response prior to salvage therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x